Document is current
Any future updates will be listed below
-
Authors
Cherkaoui, Sarah https://orcid.org/0000-0002-0636-4177
Turn, Christina S. https://orcid.org/0000-0003-3962-6740
Yuan, Yuan
Lu, Wenyun https://orcid.org/0000-0003-1787-2617
Yang, Lifeng
McBride, Matthew J.
Eigenmann, Caroline
Allen, George E.
Panasenko, Olesya O.
Zhang, Lu
Vu, Annette
Liu, Kangning
Li, Yimei
Gandhi, Om H.
Surrey, Lea F. https://orcid.org/0000-0002-6944-2232
Kienast, Sandra D.
Leidel, Sebastian A.
Wierer, Michael
White, Eileen https://orcid.org/0000-0003-2961-3065
Rabinowitz, Joshua D. https://orcid.org/0000-0002-1247-4727
Hogarty, Michael D. https://orcid.org/0000-0002-9221-4852
Morscher, Raphael J. https://orcid.org/0000-0003-3378-9266
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 21 August 2025
First Online: 24 September 2025
Competing interests
: J.D.R. is a member of the Rutgers Cancer Institute of New Jersey and the University of Pennsylvania Diabetes Research Center; a co-founder, director and stockholder in Raze Therapeutics and Farber Partners; a co-founder and stockholder in Fargo Biotechnologies; and an advisor and stockholder in Empress Therapeutics, Bantam Pharmaceuticals, Faeth Therapeutics, Colorado Research Partners and Rafael Pharmaceuticals. The University of Zürich has filed a provisional patent on combining difluormethylornithine with amino acid manipulations for therapeutic use.
